Brief: Fate Therapeutics Announces Three Presentations At The 2026 Asgct Annual Meeting Highlighting Off-The-Shelf Car T-Cell Therapy Pipeline For Cancer And Autoimmune Diseases
04/05/2026 14:10
May 4 (Reuters) - Fate Therapeutics Inc FATE.O: FATE THERAPEUTICS ANNOUNCES THREE PRESENTATIONS AT THE 2026 ASGCT ANNUAL MEETING HIGHLIGHTING OFF-THE-SHELF CAR T-CELL THERAPY PIPELINE FOR CANCER AND AUTOIMMUNE DISEASES Source text: ID:nGNX43H2B Further company coverage: FATE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview